Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function

British Journal of Pharmacology

Volumn 168, Issue 8, 2013, Pages 1889-1901

  Garcia Perez D ^a   Saez Belmonte F ^b   Laorden, M L ^a   Nunez C ^a   Milanes M V ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Ago2; DA turnover; Nurr1; opiate dependence; Pitx3; TH

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ARGONAUTE 2 PROTEIN; HYDROCHLORIC ACID; MORPHINE; NALOXONE; NUCLEAR RECEPTOR RELATED FACTOR 1; PLACEBO; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PITX3; AGO2 PROTEIN, RAT; ARGONAUTE PROTEIN; DOPAMINE; DRUG IMPLANT; HOMEODOMAIN PROTEIN; NR4A2 PROTEIN, RAT; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG USE; ELECTROPHORESIS; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; VENTRAL TEGMENTUM; WEIGHT GAIN; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; BODY WEIGHT; DRUG EFFECTS; DRUG IMPLANT; GENE EXPRESSION REGULATION; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; MESENCEPHALON; METABOLISM; PATHOLOGY; PHOSPHORYLATION; WISTAR RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ARGONAUTE PROTEINS; BODY WEIGHT; DOPAMINE; DRUG IMPLANTS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; INJECTIONS, INTRAPERITONEAL; MALE; MESENCEPHALON; MORPHINE; NALOXONE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; NUCLEUS ACCUMBENS; PHOSPHORYLATION; RATS; RATS, WISTAR; SUBSTANCE-RELATED DISORDERS; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84875457897     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12083     Document Type: Article

References (43)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Brit J Pharmacol 164 (Suppl. 1): 324.
2. Ambros V, (2004). The functions of animal microRNAs. Nature 431: 350-355.
3. Bolte S, Cordelierès FP, (2006). A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213-232.
4. Di Chiara G, (1999). Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 375: 13-30.
5. Di Chiara G, Bassareo V, (2007). Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 7: 69-76.
6. Frenois F, Cador M, Caille S, Stinus L, Le Moine C, (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377-1389.
7. Georges F, Le Moine C, Aston-Jones G, (2006). No effects of morphine on ventral tegmental dopamine neurons during withdrawal. J Neurosci 26: 5720-5726.
8. Gold LH, Stinus L, Inturrisi CE, Koob GF, (1994). Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellets implantation in the rat. Eur J Pharmacol 253: 45-51.
9. Haycock JW, Haycock DA, (1991). Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multipl-site phosphorylation in vivo and in synaptosomes. J Biol Chem 266: 5650-5657.
10. He Y, Yang C, Kirkmire CM, Wang ZJ, (2010). Regulation of opioid tolerance by let-7 family microRNA targeting the μ opioid receptor. J Neurosci 30: 10251-10258.
11. Heffner TG, Hartman JA, Seiden LS, (1980). A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13: 453-456.
12. Horvath MC, Kovacs GG, Kovari V, Majtenyi K, Hurd YL, Keller E, (2007). Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age. J Neurosci 27: 13371-13375.
13. Houshyar H, Manalo S, Dallman MF, (2004). Time-dependent alterations in mRNA expression of brain neuropeptides regulating energy balance and hypothalamo-pituitary-adrenal activity after withdrawal from intermittent morphine treatment. J Neurosci 24: 9414-9424.
14. Hutvagner G, Simard MJ, (2008). Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 9: 22-32.
15. Hwang DY, Hong S, Jeong JW, Choi S, Kim H, Kim J, et al. (2009). Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J Neurochem 111: 1202-1212.
16. Jacobs FMJ, van Erp S, van der Linden AJA, von Oerthel L, Burbach JP, Smidt MP, (2009). Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development 136: 531-540.
17. Jankovic J, Chen S, Le WD, (2005). The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77: 128-138.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
19. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. (2007). A microRNA feedback circuit in midbrain dopamine neurons. Science 317: 1220-1224.
20. Krasnova IN, Ladenheim B, Hodges AB, Volkow ND, Cadet JL, (2011). Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain. PLoS ONE 6: e19179.
21. Lenartowski R, Goc A, (2011). Epigenetic, transcriptional and posttranscriptional regulation of the tyrosine hydroxylase gene. Int J Dev Neurosci 29: 873-883.
22. Leo D, di Porzio U, Racagni G, Riva MA, Fumagalli F, Perrone-Capano C, (2007). Chronic cocaine administration modulates the expression of transcription factors involved in midbrain dopaminergic neuron function. Exp Neurol 203: 472-480.
23. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437-1441.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Nakashima A, Hayashi N, Kaneko IS, Mori K, Sabban EL, Nagatsu T, et al. (2009). Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J Neural Transm 116: 1355-1362.
26. Navarro-Zaragoza J, Núñez C, Laorden ML, Milanes MV, (2010). Effects of corticotropin-releasing factor receptor-1 (CRF1R) antagonists on the brain stress system responses to morphine withdrawal. Mol Pharmacol 77: 864-873.
27. Navarro-Zaragoza J, Núñez C, Ruiz-Medina J, Laorden ML, Valverde O, Milanés MV, (2011). CRF(2) mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats. Br J Pharmacol 162: 851-862.
28. Navarro-Zaragoza J, Hidalgo JM, Laorden ML, Milanés MV, (2012). Glucocorticoid receptors participate in the opiate withdrawal-induced stimulation of rats NTS noradrenergic activity and in the somatic signs of morphine withdrawal. Br J Pharmacol 166: 2136-2147.
29. Nestler EJ, (2001). Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119-128.
30. Nimitvilai S, Brodie MS, (2010). Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area. J Pharmacol Exp Ther 333: 555-563.
31. Núñez C, Laorden ML, Milanes MV, (2007). Regulation of serine (Ser)-31 and Ser40 tyrosine hydroxylase phosphorylation during morphine withdrawal in the hypothalamic paraventricular nucleus and nucleus tractus solitarius-A2 cell group. Role of ERK1/2. Endocrinology 148: 5780-5793.
32. Núñez C, Földes A, Pérez-Flores D, García-Borrõn JC, Laorden ML, Kovács KJ, et al. (2009). Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase (TH) mRNA expression, phosphorylation and enzyme activity in the nucleus of the solitary tract (NTS-A2) during morphine withdrawal. Endocrinology 150: 3118-3127.
33. Paxinos G, Watson C, (2007). The Rat Brain in Stereotaxic Coordinates. Academic Press: Amsterdam.
34. Reddy SD, Rayala SK, Ohshiro K, Pakala SB, Kobori N, Dash P, et al. (2011). Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc Natl Acad Sci U S A 108: 4200-4205.
35. Salvatore MF, Pruett BS, (2012). Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways. PLoS ONE 7: e29867.
36. Salvatore MF, Pruett BS, Spann SL, Dempsey C, (2009). Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS ONE 4: e8466.
37. Sanchez-Simon FM, Zhang XX, Loh HH, Law PY, Rodriguez RE, (2010). Morphine regulates dopaminergic neuron differentiation via miR-133b. Mol Pharmacol 78: 935-942.
38. Schaefer A, Im HI, Veno MT, Fowler CD, Min A, Intrator A, et al. (2010). Argonaute 2 in dopamine 2 receptor-coexpressing neurons regulates cocaine addiction. J Exp Med 207: 1843-1851.
39. Smidt MP, van Schaick HSA, Lanctôt C, Tremblay JJ, Cox JJ, van der, Kleij AAM, et al. (1997). A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. Proc Natl Acad Sci U S A 94: 13305-13310.
40. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL, Burbach JP, (2000). A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci 3: 337-341.
41. Smidt MP, Smits SM, Burbach JP, (2004). Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra. Cell Tissue Res 318: 35-43.
42. Tank AW, Xu L, Chen X, Radcliffe P, Sterling CR, (2008). Post-transcriptional regulation of tyrosine hydroxylase expression in adrenal medulla and brain. Ann N Y Acad Sci 1148: 238-248.
43. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F, (2009). Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl. 1): 3-8.